# The Effect of Dexamethasone 12 mg vs 6 mg on Thromboembolic Events in Patients With Critical COVID-19

> **NCT05195242** · PHASE3 · COMPLETED · sponsor: **Karolinska Institutet** · enrollment: 445 (actual)

## Conditions studied

- COVID-19
- Thrombosis Embolism
- Bleeding

## Interventions

- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT05195242
- **Lead sponsor:** Karolinska Institutet
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-27
- **Primary completion:** 2021-06-20
- **Final completion:** 2021-06-30
- **Target enrollment:** 445 (ACTUAL)
- **Last updated:** 2022-06-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05195242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05195242, "The Effect of Dexamethasone 12 mg vs 6 mg on Thromboembolic Events in Patients With Critical COVID-19". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT05195242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*